Tranexamic Acid Inhibits Melanogenesis: The PKA-CREB-MITF Pathway Mechanism and Clinical Evidence

Tranexamic Acid Inhibits Melanogenesis: The PKA-CREB-MITF Pathway Mechanism and Clinical Evidence

Tranexamic acid (TXA) inhibits melanogenesis through multiple converging pathways, with the PKA-CREB-MITF signalling axis now identified as a central mechanism. Originally developed as an antifibrinolytic agent, TXA has emerged as one of the most studied non-hydroquinone treatments for melasma and hyperpigmentation disorders. A 2025 global consensus project convened by Passeron et al. and published in the Journal of the European Academy of Dermatology and Venereology (2026;40:760–772) now positions TXA as a key therapeutic option within an evidence-based international framework for managing melanin hyperpigmentation disorders.

How Tranexamic Acid Inhibits Melanogenesis: The PKA-CREB-MITF Axis

The anti-melanogenic mechanism of TXA operates at multiple levels of the pigmentation cascade. Central to its action is inhibition of the plasminogen/plasmin system — UV radiation upregulates plasmin activity in keratinocytes, which in turn releases arachidonic acid and prostaglandin E2, both potent stimulators of melanogenesis. By blocking plasminogen binding to keratinocytes, TXA interrupts this paracrine signalling loop between keratinocytes and melanocytes.

New molecular detail emerged in late 2025. Bae et al. demonstrated in Experimental Dermatology (2025;34:e70194) that TXA directly inhibits 17β-estradiol-induced melanogenesis through the PKA-CREB-MITF pathway. This finding is clinically significant because estrogen is a well-established trigger for melasma, and the PKA-CREB-MITF cascade represents the canonical transcriptional pathway governing TYR, TRP-1, and TRP-2 gene expression. The study confirmed that TXA downregulates MITF (microphthalmia-associated transcription factor) — the master regulator of melanogenic enzyme transcription — through cAMP-dependent PKA-CREB signal attenuation.

Additionally, TXA reduces endothelin-1 secretion from UV-irradiated keratinocytes and lowers stem cell factor (SCF) levels, both potent melanogenic stimuli. The net effect is a multi-pronged suppression of melanin synthesis without direct cytotoxicity to melanocytes, which distinguishes TXA from harsher depigmenting agents.

Delivery Innovation: Lipidic Vesicular Systems and Niosomal Formulations

A 2025 review by Soo et al. in Advanced Pharmaceutical Bulletin (2025;15:574–587) systematically examined lipidic vesicular carriers for TXA delivery. Conventional topical TXA faces penetration challenges due to its hydrophilic nature (log P ≈ −2.0). Liposomes, ethosomes, and niosomes significantly enhance epidermal and dermal delivery by encapsulating TXA within phospholipid bilayers or non-ionic surfactant vesicles, achieving superior stratum corneum penetration compared to aqueous solutions.

Clinical translation followed quickly. Ghasemiyeh et al. published a randomized, double-blind, case-controlled trial in Scientific Reports (2025;15:42739) directly comparing niosomal TXA/niacinamide cream against conventional TXA/niacinamide and hydroquinone 4% cream in melasma patients. The niosomal formulation demonstrated MASI score reductions comparable to hydroquinone — with a more favorable tolerability profile and no risk of exogenous ochronosis, the dose-dependent complication that limits long-term hydroquinone use.

Thiamidol, TXA, and the Shifting Therapeutic Landscape

A 2025 comparative review by Suliman et al. in the Journal of Dermatological Treatment (2025;36:2591502) evaluated the emerging topical melasma pipeline. Among chemical agents, thiamidol (isobutylamido thiazolyl resorcinol) demonstrated comparable efficacy to hydroquinone with markedly better tolerability. TXA and metformin both achieved MASI score improvements similar to triple-combination therapy (hydroquinone + tretinoin + corticosteroid), but with significantly fewer adverse events. This positions TXA as a viable first-line topical agent, particularly for patients who cannot tolerate or wish to avoid hydroquinone-based regimens.

Beyond Pigment: Basement Membrane Restoration

Perhaps the most unexpected finding comes from optical coherence tomography research. Liang et al. reported in Journal of Biophotonics (2026;19:e202500491) that longitudinal OCT monitoring revealed significant basement membrane recovery following TXA treatment in melasma patients. Melasma is increasingly understood not merely as a melanocyte disorder but as a photoaging phenotype involving basement membrane disruption, solar elastosis, and increased vascularization. TXA’s ability to promote BM restoration — beyond its melanogenic effects — suggests therapeutic benefits that extend into dermal remodelling, potentially explaining why clinical improvement often outlasts the treatment period.

Clinical Implications and Future Directions

The expanding evidence base for TXA reflects a broader shift toward mechanism-driven formulation. For the cosmetic scientist, three actionable insights emerge from the 2025–2026 literature:

• Pathway targeting: TXA’s activity at the PKA-CREB-MITF node provides a rational basis for combination with complementary actives that target alternative melanogenic pathways — for example, pairing with niacinamide (which inhibits melanosome transfer via PAR-2 blockade) rather than stacking redundant tyrosinase inhibitors.
• Delivery matters: Niosomal and ethosomal carriers convert TXA from a penetration-limited active into a clinically competitive alternative to hydroquinone. Formulation scientists should consider vesicular delivery when developing TXA-based products.
• BM repair as an endpoint: The OCT evidence for basement membrane restoration suggests that efficacy assessments should look beyond melanin index alone. Dermal remodelling markers may represent an underexplored dimension of TXA’s clinical value.

With RCT-level evidence now published across multiple independent research groups and a formal international consensus supporting its use, TXA has moved beyond off-label repurposing into an evidence-grounded cornerstone of hyperpigmentation management. The 2025 Bae et al. elucidation of the PKA-CREB-MITF mechanism fills a critical gap in the mechanistic understanding that formulators and dermatologists alike have been waiting for.

References: Bae YJ et al. Exp Dermatol 2025;34:e70194. | Passeron T et al. J Eur Acad Dermatol Venereol 2026;40:760–772. | Ghasemiyeh P et al. Sci Rep 2025;15:42739. | Suliman RS et al. J Dermatolog Treat 2025;36:2591502. | Soo XL et al. Adv Pharm Bull 2025;15:574–587. | Liang J et al. J Biophotonics 2026;19:e202500491.